Impact of the National Health Fund policy on hormone treatment for prostate cancer in Jamaica

Revista Panamericana de Salud Publica/Pan American Journal of Public Health

Volumn 29, Issue 6, 2011, Pages 404-408

  Morrison, Belinda F ^a   Aiken, William D ^a   Reid, Marvin E ^a  

^a UNIVERSITY OF THE WEST INDIES   (Jamaica)

Author keywords

Androgen antagonists, therapeutic use; Jamaica; Orchiectomy; Prescription fees; Prostatic neoplasms

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN; GONADORELIN;

AGE STRUCTURE; ANDROGEN; CANCER; CASTRATION; DATABASE; DISEASE TREATMENT; DRUG; HEALTH RISK; HOSPITAL SECTOR; PATHOLOGY; POLICY MAKING;

ADENOCARCINOMA; AGED; BIOPSY; COMPARATIVE STUDY; DRUG POTENTIATION; ECONOMICS; FEE; FINANCIAL MANAGEMENT; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH INSURANCE; HUMAN; JAMAICA; MALE; ORCHIECTOMY; PATHOLOGY; PATIENT PREFERENCE; PROSTATE; PROSTATE TUMOR; PSYCHOLOGICAL ASPECT; PUBLIC HEALTH; RETROSPECTIVE STUDY; REVIEW; UTILIZATION REVIEW;

ADENOCARCINOMA; AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BIOPSY; ESTROGENS; FINANCING, GOVERNMENT; GONADOTROPIN-RELEASING HORMONE; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; JAMAICA; MALE; NATIONAL HEALTH PROGRAMS; ORCHIECTOMY; PATIENT PREFERENCE; PRESCRIPTION FEES; PROSTATE; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

JAMAICA;

EID: 80051517386     PISSN: 10204989     EISSN: 16805348     Source Type: Journal    
DOI: 10.1590/S1020-49892011000600004     Document Type: Review

References (23)

1. Loblaw DA, Mendelson DS, Talcott JA, Virgo KS, Somerfield MR, Ben-Josef E, et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol. 2004;22(14):2927-41. (Pubitemid 41079913)
2. Huggins C. Effect of Orchiectomy and Irradiation on Cancer of the Prostate. Ann Surg. 1942;115(6):1192-200.
3. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002; 360(9327):103-6.
4. Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol. 1994;152(5 Pt 2): 1850-7. (Pubitemid 24322643)
5. Cassileth BR, Soloway MS, Vogelzang NJ, Chou JM, Schellhammer PD, Seidmon EJ, et al. Quality of life and psychosocial status in stage D prostate cancer. Zoladex Prostate Cancer Study Group. Qual Life Res. 1992;1(5): 323-9.
6. Lucas MD, Strijdom SC, Berk M, Hart GA. Quality of life, sexual functioning and sex role identity after surgical orchidectomy in patients with prostatic cancer. Scand J Urol Nephrol. 1995;29(4):497-500. (Pubitemid 26015164)
7. Barry MJ, Delorenzo MA, Walker-Corkery ES, Lucas FL, Wennberg DC. The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study. BJU Int. 2006;98(5): 973-8. (Pubitemid 44536442)
8. Bank of Jamaica. Exchange rates. Available from: http://www.boj.org.jm/ exchange-rates-month.php. Accessed on 28 March 2011.
9. Gibson T, Blake G, Hanchard B, Waugh N, McNaughton D. Age-specific incidence of cancer in Kingston and St. Andrew, 1998-2002. West Indian Med J. 2008;57(2):81-9.
10. Blake G, Hanchard B, Mitchell K, Simpson D, Waugh N, Wolff C, et al. Jamaica cancer mortality statistics, 1999. West Indian Med J. 2002;51(2):64-7. (Pubitemid 34918939)
11. Klotz L. Hormone therapy for patients with prostate carcinoma. Cancer. 2000;88(12 Suppl):3009-14. (Pubitemid 30413184)
12. Byar DP. Proceedings of the Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer. 1973;32(5):1126-30.
13. Cassileth BR, Soloway MS, Vogelzang NJ, Schellhammer PS, Seidmon EJ, Hait HI, et al. Patients' choice of treatment in stage D prostate cancer. Urology. 1989;33(5 Suppl): 57-62. (Pubitemid 19123268)
14. Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr.1988(7): 165-70.
15. Blackard CE, Doe RP, Mellinger GT, Byar DP. Incidence of cardiovascular disease and death in patients receiving diethylstilbestrol for carcinoma of the prostate. Cancer. 1970;26(2): 249-56.
16. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The Leuprolide Study Group. N Engl J Med. 1984;311(20): 1281-6.
17. Ockrim JL, Lalani EN, Banks LM, Svensson WE, Blomley MJ, Patel S, et al. Transdermal estradiol improves bone density when used as single agent therapy for prostate cancer. J Urol. 2004;172(6 Pt 1):2203-7. (Pubitemid 39507492)
18. Bland LB, Garzotto M, DeLoughery TG, Ryan CW, Schuff KG, Wersinger EM, et al. Phase II study of transdermal estradiol in androgenindependent prostate carcinoma. Cancer. 2005;103(4):717-23. (Pubitemid 40216399)
19. Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials. Prostate Cancer Trialists' Collaborative Group. Lancet. 2000;355(9214): 1491-8.
20. Migliari R, Muscas G, Usai E. Effect of Casodex on sleep-related erections in patients with advanced prostate cancer. J Urol. 1992;148(2 Pt 1):338-41.
21. Kimura K, Markowski M, Bowen C, Gelmann EP. Androgen blocks apoptosis of hormonedependent prostate cancer cells. Cancer Res. 2001;61(14):5611-8. (Pubitemid 32700276)
22. Abrahamsson PA. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2010;57(1): 49-59.
23. Wilks R, Younger N, Tulloch-Reid M, McFarlane S, Francis D. Jamaica health and lifestyle survey, 2007-2008. Kingston: Epidemiology Research Unit; 2008.